Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Dana Tupa is active.

Publication


Featured researches published by Dana Tupa.


The Lancet Gastroenterology & Hepatology | 2018

Anti-IgE treatment with oral immunotherapy in multifood allergic participants: a double-blind, randomised, controlled trial

Sandra Andorf; Natasha Purington; Whitney Block; Andrew Long; Dana Tupa; Erica Brittain; Amanda Rudman Spergel; Manisha Desai; Stephen J. Galli; Kari C. Nadeau; R. Sharon Chinthrajah

Summary BACKGROUND Despite progress in single food oral immunotherapy (OIT), there is little evidence concerning the safety and efficacy of treating individuals with multiple food (multifood) allergies. We conducted a pilot study testing whether anti-IgE (omalizumab) combined with multifood OIT benefitted multifood allergic patients. METHODS In this blinded, phase 2 clinical trial conducted at Stanford University, 48 participants, aged 4-15 years, with multifood allergies validated by double-blind, placebo-controlled food challenges (DBPCFCs) to their offending foods were block randomized (3:1) to receive multifood OIT to 2-5 foods, together with omalizumab (n=36) or placebo (n=12). Omalizumab or placebo was administered subcutaneously for 16 weeks with OIT starting at week 8; omalizumab or placebo was stopped 20 weeks before exit DBPCFCs (week 36) to determine the primary endpoint: the proportion of participants who passed DBPCFCs to at least 2 of their offending foods. This completed trial is registered with ClinicalTrials.gov, . FINDINGS At week 36, a significantly greater proportion of the omalizumab (30/36, 83%) vs. placebo (4/12, 33%) participants passed DBPCFCs to 2 g protein for ≥ 2 of their offending foods (odds ratio (OR): 10, 95% confidence interval (CI): 1·8, 58·3, P=0·004). The same individuals also tolerated 4 g protein of ≥ 2 foods (secondary endpoint, P=0·004). A greater proportion of omalizumab (13/17, 77%) vs. placebo (0/5, 0%) participants passed a DBPCFC to 2 g protein for ≥ 4 of their offending foods (OR: 33, 95% CI: 1·9, ∞, P=0·01). All participants completed the study. There were no serious or severe (≥ grade 3) adverse events. INTERPRETATION In multifood allergic patients, omalizumab improves the efficacy of multifood OIT and enables safe and rapid desensitization. FUNDING NIH U19 AADCRC and Opportunity Fund, Sean N. Parker Center for Allergy and Asthma Research at Stanford University, Simons Foundation, Myra Reinhard Foundation, FARE Center of Excellence, Department of Pathology, and Department of Pediatrics, Stanford University.


The Journal of Allergy and Clinical Immunology: In Practice | 2017

Association of Clinical Reactivity with Sensitization to Allergen Components in Multifood-Allergic Children

Sandra Andorf; Magnus P. Borres; Whitney Block; Dana Tupa; Jennifer Bollyky; Vanitha Sampath; Arnon Elizur; Jonas Lidholm; Joseph E. Jones; Stephen J. Galli; Rebecca S. Chinthrajah; Kari C. Nadeau

BACKGROUND Thirty percent of children with food allergies have multiple simultaneous allergies; however, the features of these multiple allergies are not well characterized serologically or clinically. OBJECTIVE We comprehensively evaluated 60 multifood-allergic patients by measuring serum IgE to key allergen components, evaluating clinical histories and medication use, performing skin tests, and conducting double-blind, placebo-controlled food challenges (DBPCFCs). METHODS Sixty participants with multiple food allergies were characterized by clinical history, DBPCFCs, total IgE, specific IgE, and component-resolved diagnostics (IgE and IgG4) data. The food allergens tested were almond, egg, milk, sesame, peanut, pecan, walnut, hazelnut, cashew, pistachio, soy, and wheat. RESULTS Our data demonstrate that of the reactions observed during a graded DBPCFC, gastrointestinal reactions occurred more often in boys than in girls, as well as in individuals with high levels of IgE to 2S albumins from cashew, walnut, and hazelnut. Certain food allergies often occurred concomitantly in individuals (ie, cashew/pistachio and walnut/pecan/hazelnut). IgE testing to components further corroborated serological relationships between and among these clustered food allergies. CONCLUSIONS Associations of certain food allergies were shown by DBPCFC outcomes as well as by correlations in IgE reactivity to structurally related food allergen components. Each of these criteria independently demonstrated a significant association between allergies to cashew and pistachio, as well as among allergies to walnut, pecan, and hazelnut.


Annals of Allergy Asthma & Immunology | 2017

Deciphering the black box of food allergy mechanisms.

Vanitha Sampath; Dana Tupa; Michelle T. Graham; Talal A. Chatila; Jonathan M. Spergel; Kari C. Nadeau

OBJECTIVE To review our current understanding of immunotherapy, the immune mechanisms underlying food allergy, and the methodological advances that are furthering our understanding of the role of immune cells and other molecules in mediating food allergies. DATA SOURCES Literature searches were performed using the following combination of terms: allergy, immunotherapy, food, and mechanisms. Data from randomized clinical studies using state-of-the-art mechanistic tools were prioritized. STUDY SELECTIONS Articles were selected based on their relevance to food allergy. RESULTS Current standard of care for food allergies is avoidance of allergenic foods and the use of epinephrine in case of severe reaction during unintentional ingestion. During the last few decades, great strides have been made in understanding the cellular and molecular mechanisms underlying food allergy, and this information is spearheading the development of exciting new treatments. CONCLUSION Immunotherapy protocols are effective in desensitizing individuals to specific allergens; however, recurrence of allergic sensitization is common after discontinuation of therapy. Interestingly, in a subset of individuals, immunotherapy is protective against allergens even after discontinuation of immunotherapy. Whether this protection is permanent is currently unknown because of inadequate long-term follow-up data. Research on understanding the underlying mechanisms may assist in modifying protocols to improve outcome and enable sustained unresponsiveness, rather than a temporary relief against food allergies. The cellular changes brought about by immunotherapy are still a black box, but major strides in our understanding are being made at an exciting pace.


Pediatric Clinics of North America | 2015

Diagnosis of Food Allergy

Rebecca S. Chinthrajah; Dana Tupa; Benjamin T. Prince; Whitney Block; Jaime S. Rosa; Anne Marie Singh; Kari C. Nadeau

The prevalence of food allergies has been on the increase over the last 2 decades. Diagnosing food allergies can be complicated, as there are multiple types that have distinct clinical and immunologic features. Food allergies are broadly classified into immunoglobulin E (IgE)-mediated, non-IgE-mediated, or mixed food allergic reactions. This review focuses on the clinical manifestations of the different categories of food allergies and the different tests available to guide the clinician toward an accurate diagnosis.


Annals of Allergy Asthma & Immunology | 2018

High dimensional immune biomarkers demonstrate differences in phenotypes and endotypes in food allergy and asthma

R. Sharon Chinthrajah; Natasha Purington; Vanitha Sampath; Sandra Andorf; Monali Manohar; Mary Prunicki; Xiaoying Zhou; Dana Tupa; Kari C. Nadeau


Annals of Allergy Asthma & Immunology | 2017

OR076 Age-related variations in reactions during positive oral food challenge to peanut protein

Sayantani B. Sindher; A. Long; Dana Tupa; Sandra Andorf; Natasha Purington; R. Chinthrajah; Kari C. Nadeau


Allergy, Asthma & Clinical Immunology | 2017

Observational long-term follow-up study of rapid food oral immunotherapy with omalizumab

Sandra Andorf; Monali Manohar; Tina Dominguez; Whitney Block; Dana Tupa; Rohun A. Kshirsagar; Vanitha Sampath; R. Sharon Chinthrajah; Kari C. Nadeau


Allergy, Asthma & Clinical Immunology | 2017

Feasibility of sustained response through long-term dosing in food allergy immunotherapy

Sandra Andorf; Monali Manohar; Tina Dominguez; Whitney Block; Dana Tupa; Rohun A. Kshirsagar; Vanitha Sampath; R. Sharon Chinthrajah; Kari C. Nadeau


The Journal of Allergy and Clinical Immunology | 2016

Long-Term Follow-up of Oral Immunotherapy for Multiple Food Allergies

Sonia Singh; Rohun A. Kshirsagar; Tina Dominguez; Dana Tupa; Whitney Block; R. Sharon Chinthrajah; Kari C. Nadeau


The Journal of Allergy and Clinical Immunology | 2016

Severity of Reactions to Oral Peanut Challenges in Children and Adults

R. Sharon Chinthrajah; Jaime S. Rosa; Dana Tupa; Bridget Smith; Ruchi S. Gupta; Stephen J. Galli; Kari C. Nadeau

Collaboration


Dive into the Dana Tupa's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge